ID   ACVR1_HUMAN             Reviewed;         509 AA.
AC   Q04771;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   05-OCT-2010, entry version 116.
DE   RecName: Full=Activin receptor type-1;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor type I;
DE            Short=ACTR-I;
DE   AltName: Full=Activin receptor-like kinase 2;
DE            Short=ALK-2;
DE   AltName: Full=Serine/threonine-protein kinase receptor R1;
DE            Short=SKR1;
DE   AltName: Full=TGF-B superfamily receptor type I;
DE            Short=TSR-I;
DE   Flags: Precursor;
GN   Name=ACVR1; Synonyms=ACVRLK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=93286114; PubMed=8389764;
RA   Matsuzaki K., McKeehan W.L.;
RT   "A widely expressed transmembrane serine/threonine kinase that does
RT   not bind activin, inhibin, transforming growth factor beta, or bone
RT   morphogenic factor.";
RL   J. Biol. Chem. 268:12719-12723(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   MEDLINE=93390967; PubMed=8397373;
RA   ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J.,
RA   Toyoshima H., Heldin C.-H., Miyazono K.;
RT   "Activin receptor-like kinases: a novel subclass of cell-surface
RT   receptors with predicted serine/threonine kinase activity.";
RL   Oncogene 8:2879-2887(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-501, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18187866; DOI=10.2116/analsci.24.161;
RA   Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.;
RT   "Automated phosphoproteome analysis for cultured cancer cells by two-
RT   dimensional nanoLC-MS using a calcined titania/C18 biphasic column.";
RL   Anal. Sci. 24:161-166(2008).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226 AND SER-501, AND
RP   MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 172-499 IN COMPLEX WITH
RP   FKBP1A.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the kinase domain of type I activin receptor
RT   (ACVR1) in complex with FKBP12 and dorsomorphin.";
RL   Submitted (JUN-2009) to the PDB data bank.
RN   [7]
RP   VARIANT FOP HIS-206.
RX   PubMed=16642017; DOI=10.1038/ng1783;
RA   Shore E.M., Xu M., Feldman G.J., Fenstermacher D.A., Brown M.A.,
RA   Kaplan F.S.;
RT   "A recurrent mutation in the BMP type I receptor ACVR1 causes
RT   inherited and sporadic fibrodysplasia ossificans progressiva.";
RL   Nat. Genet. 38:525-527(2006).
RN   [8]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-15; PHE-41; GLN-47 AND SER-115.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [9]
RP   VARIANTS FOP 197-PRO-PHE-198 DELINS LEU; HIS-206; GLU-207; ARG-328;
RP   TRP-328; GLU-328; ASP-356 AND PRO-375.
RX   PubMed=19085907; DOI=10.1002/humu.20868;
RA   Kaplan F.S., Xu M., Seemann P., Connor J.M., Glaser D.L., Carroll L.,
RA   Delai P., Fastnacht-Urban E., Forman S.J., Gillessen-Kaesbach G.,
RA   Hoover-Fong J., Koester B., Pauli R.M., Reardon W., Zaidi S.A.,
RA   Zasloff M., Morhart R., Mundlos S., Groppe J., Shore E.M.;
RT   "Classic and atypical fibrodysplasia ossificans progressiva (FOP)
RT   phenotypes are caused by mutations in the bone morphogenetic protein
RT   (BMP) type I receptor ACVR1.";
RL   Hum. Mutat. 30:379-390(2009).
RN   [10]
RP   VARIANTS FOP ILE-202 AND GLU-328.
RX   PubMed=19330033; DOI=10.1371/journal.pone.0005005;
RA   Petrie K.A., Lee W.H., Bullock A.N., Pointon J.J., Smith R.,
RA   Russell R.G., Brown M.A., Wordsworth B.P., Triffitt J.T.;
RT   "Novel mutations in ACVR1 result in atypical features in two
RT   fibrodysplasia ossificans progressiva patients.";
RL   PLoS ONE 4:E5005-E5005(2009).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting
CC       of two type II and two type I transmembrane serine/threonine
CC       kinases. Type II receptors phosphorylate and activate type I
CC       receptors which autophosphorylate, then bind and activate SMAD
CC       transcriptional regulators. Receptor for activin. May be involved
CC       for left-right pattern formation during embryogenesis (By
CC       similarity).
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR: Magnesium or manganese (By similarity).
CC   -!- SUBUNIT: Interacts with FKBP1A.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Expressed in normal parenchymal cells,
CC       endothelial cells, fibroblasts and tumor-derived epithelial cells.
CC   -!- DISEASE: Defects in ACVR1 are a cause of fibrodysplasia ossificans
CC       progressiva (FOP) [MIM:135100]. FOP is a rare autosomal dominant
CC       disorder of skeletal malformations and progressive extraskeletal
CC       ossification. Heterotopic ossification in FOP begins in childhood
CC       and can be induced by trauma or may occur without warning. Bone
CC       formation is episodic and progressive, leading to extra-articular
CC       ankylosis of all major joints of the axial and appendicular
CC       skeleton, rendering movement impossible.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily.
CC   -!- SIMILARITY: Contains 1 GS domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ACVR1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L02911; AAA36614.1; -; mRNA.
DR   EMBL; Z22534; CAA80256.1; -; mRNA.
DR   EMBL; BC033867; AAH33867.1; -; mRNA.
DR   IPI; IPI00029219; -.
DR   PIR; A45992; A45992.
DR   RefSeq; NP_001096.1; -.
DR   RefSeq; NP_001104537.1; -.
DR   UniGene; Hs.470316; -.
DR   PDB; 3H9R; X-ray; 2.35 A; A=172-499.
DR   PDB; 3MTF; X-ray; 2.15 A; A/B=201-499.
DR   PDBsum; 3H9R; -.
DR   PDBsum; 3MTF; -.
DR   ProteinModelPortal; Q04771; -.
DR   SMR; Q04771; 33-108.
DR   DIP; DIP-212N; -.
DR   MINT; MINT-1340145; -.
DR   STRING; Q04771; -.
DR   PhosphoSite; Q04771; -.
DR   PRIDE; Q04771; -.
DR   Ensembl; ENST00000263640; ENSP00000263640; ENSG00000115170.
DR   Ensembl; ENST00000409283; ENSP00000387273; ENSG00000115170.
DR   Ensembl; ENST00000410057; ENSP00000387127; ENSG00000115170.
DR   Ensembl; ENST00000434821; ENSP00000405004; ENSG00000115170.
DR   GeneID; 90; -.
DR   KEGG; hsa:90; -.
DR   UCSC; uc002tzm.2; human.
DR   CTD; 90; -.
DR   GeneCards; GC02M158594; -.
DR   H-InvDB; HIX0002524; -.
DR   HGNC; HGNC:171; ACVR1.
DR   HPA; HPA007505; -.
DR   MIM; 102576; gene.
DR   MIM; 135100; phenotype.
DR   Orphanet; 337; Fibrodysplasia ossificans progressiva.
DR   PharmGKB; PA24492; -.
DR   eggNOG; prNOG09977; -.
DR   HOGENOM; HBG314718; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; Q04771; -.
DR   OMA; AFPSPSM; -.
DR   OrthoDB; EOG983GQ0; -.
DR   PhylomeDB; Q04771; -.
DR   BRENDA; 2.7.10.2; 247.
DR   BRENDA; 2.7.11.30; 247.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   NextBio; 335; -.
DR   ArrayExpress; Q04771; -.
DR   Bgee; Q04771; -.
DR   CleanEx; HS_ACVR1; -.
DR   Genevestigator; Q04771; -.
DR   GermOnline; ENSG00000115170; Homo sapiens.
DR   GO; GO:0048179; C:activin receptor complex; IDA:UniProtKB.
DR   GO; GO:0048185; F:activin binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC.
DR   GO; GO:0048184; F:follistatin binding; NAS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IDA:UniProtKB.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:HGNC.
DR   GO; GO:0032926; P:negative regulation of activin receptor sig...; IMP:HGNC.
DR   GO; GO:0043066; P:negative regulation of apoptosis; IMP:HGNC.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IMP:HGNC.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0045669; P:positive regulation of osteoblast different...; IMP:BHF-UCL.
DR   GO; GO:0045941; P:positive regulation of transcription; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IDA:HGNC.
DR   GO; GO:0007179; P:transforming growth factor beta receptor si...; IDA:UniProtKB.
DR   InterPro; IPR000333; Activin_II_recpt.
DR   InterPro; IPR000472; Activin_rcpt.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR003605; TGF_beta_rcpt_GS.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SMART; SM00467; GS; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome; Disease mutation;
KW   Glycoprotein; Kinase; Magnesium; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Serine/threonine-protein kinase; Signal; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     20       By similarity.
FT   CHAIN        21    509       Activin receptor type-1.
FT                                /FTId=PRO_0000024394.
FT   TOPO_DOM     21    123       Extracellular (Potential).
FT   TRANSMEM    124    146       Helical; (Potential).
FT   TOPO_DOM    147    509       Cytoplasmic (Potential).
FT   DOMAIN      178    207       GS.
FT   DOMAIN      208    502       Protein kinase.
FT   NP_BIND     214    222       ATP (By similarity).
FT   ACT_SITE    336    336       Proton acceptor (By similarity).
FT   BINDING     235    235       ATP (By similarity).
FT   MOD_RES     226    226       Phosphoserine.
FT   MOD_RES     501    501       Phosphoserine.
FT   CARBOHYD    102    102       N-linked (GlcNAc...) (Potential).
FT   VARIANT      15     15       A -> G (in dbSNP:rs13406336).
FT                                /FTId=VAR_041392.
FT   VARIANT      41     41       S -> F (in dbSNP:rs55957214).
FT                                /FTId=VAR_041393.
FT   VARIANT      47     47       H -> Q (in dbSNP:rs34056189).
FT                                /FTId=VAR_041394.
FT   VARIANT     115    115       P -> S (in a melanoma sample; somatic
FT                                mutation).
FT                                /FTId=VAR_041395.
FT   VARIANT     197    198       PF -> L (in FOP; variant phenotype).
FT                                /FTId=VAR_058418.
FT   VARIANT     202    202       R -> I (in FOP; with some atypical
FT                                features).
FT                                /FTId=VAR_058419.
FT   VARIANT     206    206       R -> H (in FOP).
FT                                /FTId=VAR_028444.
FT   VARIANT     207    207       Q -> E (in FOP; with some atypical
FT                                features).
FT                                /FTId=VAR_058420.
FT   VARIANT     328    328       G -> E (in FOP; variant phenotype).
FT                                /FTId=VAR_058421.
FT   VARIANT     328    328       G -> R (in FOP; variant phenotype).
FT                                /FTId=VAR_058422.
FT   VARIANT     328    328       G -> W (in FOP; variant phenotype).
FT                                /FTId=VAR_058423.
FT   VARIANT     356    356       G -> D (in FOP; variant phenotype).
FT                                /FTId=VAR_058424.
FT   VARIANT     375    375       R -> P (in FOP; variant phenotype).
FT                                /FTId=VAR_058425.
FT   HELIX       180    185
FT   HELIX       198    205
FT   STRAND      222    224
FT   STRAND      233    237
FT   HELIX       239    241
FT   HELIX       242    254
FT   STRAND      267    271
FT   STRAND      278    283
FT   HELIX       291    297
FT   HELIX       302    313
FT   HELIX       317    320
FT   STRAND      331    333
FT   HELIX       339    341
FT   STRAND      342    345
FT   STRAND      350    352
FT   STRAND      359    361
FT   HELIX       379    381
FT   HELIX       384    387
FT   HELIX       396    406
FT   HELIX       410    415
FT   TURN        430    434
FT   HELIX       441    448
FT   HELIX       459    463
FT   HELIX       465    475
FT   HELIX       482    484
FT   HELIX       488    498
SQ   SEQUENCE   509 AA;  57153 MW;  E2B0F051D19DD052 CRC64;
     MVDGVMILPV LIMIALPSPS MEDEKPKVNP KLYMCVCEGL SCGNEDHCEG QQCFSSLSIN
     DGFHVYQKGC FQVYEQGKMT CKTPPSPGQA VECCQGDWCN RNITAQLPTK GKSFPGTQNF
     HLEVGLIILS VVFAVCLLAC LLGVALRKFK RRNQERLNPR DVEYGTIEGL ITTNVGDSTL
     ADLLDHSCTS GSGSGLPFLV QRTVARQITL LECVGKGRYG EVWRGSWQGE NVAVKIFSSR
     DEKSWFRETE LYNTVMLRHE NILGFIASDM TSRHSSTQLW LITHYHEMGS LYDYLQLTTL
     DTVSCLRIVL SIASGLAHLH IEIFGTQGKP AIAHRDLKSK NILVKKNGQC CIADLGLAVM
     HSQSTNQLDV GNNPRVGTKR YMAPEVLDET IQVDCFDSYK RVDIWAFGLV LWEVARRMVS
     NGIVEDYKPP FYDVVPNDPS FEDMRKVVCV DQQRPNIPNR WFSDPTLTSL AKLMKECWYQ
     NPSARLTALR IKKTLTKIDN SLDKLKTDC
//
